The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
The Microbiota Makes for Good Therapy: The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967 ) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971 ) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and that therapeutic responses may be improved via its modulation (13, 14)”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [14]
In the citing paper
“The P-ESC was considered representative of baseline microbiome data due to observations that the microbiome of patients treated with anti-PD-1, unlike anti-CTLA-4 or chemotherapy, is stable early after therapy initiation17–19.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [19]
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“The gut microbiome has been shown to have multiple effects on tumor biology, such as the transformation process, tumor progression, and the response to anticancer therapies including immunotherapy (21-29).”
From The human tumor microbiome is composed of tumor type–specific intracellular bacteria (2020) · cites this paper as [26]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences
Li, W., & Godzik, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl158 · Cited by 11,410
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 2×
“Finally, monoassociation of tumor-bearing GF mice with SFB, which promotes Th17 cell differentiation in the LP (1, 13, 14) also had a detrimental impact on the tumor growthinhibitory effect of CTX (Fig.”
BackgroundImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Some antineoplastic agents mediate part of their anticancer activity by stimulating anticancer immune responses (6).”
BackgroundSelf-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“S6A) and is required for the therapeutic success of anticancer chemotherapies in several tumor models (19).”
BackgroundSelf-citationInnate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells
Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D. R., Benoist, C., & Mathis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.001 · Cited by 1,577
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Self-citation
Research works printed but not linked: 1
- 10.1073/pnas.1113744109 · DOI · Paper page
Cited by
Items 101–200 of 1,012
Norenhag, J., Du, J., Olovsson, M., Verstraelen, H., Engstrand, L., & Brusselaers, N. (2020) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15854 · Cited by 383
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
Modulating the microbiome to improve therapeutic response in cancer
McQuade, J. L., Daniel, C. R., Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30952-5 · Cited by 376
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Thomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 367
Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect
Sun, L., Suo, C., Li, S.-T., Zhang, H., & Gao, P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.005 · Cited by 363
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Schwabe, R. F., & Greten, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.016 · Cited by 363
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
The Intestinal Metabolome: An Intersection Between Microbiota and Host
Ursell, L. K., Haiser, H. J., Van Treuren, W., Garg, N., Reddivari, L., Vanamala, J., Dorrestein, P. C., Turnbaugh, P. J., & Knight, R. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.001 · Cited by 355
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349
Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy
Górska, A., Przystupski, D., Niemczura, M. J., & Kulbacka, J. (2019) · Current Microbiology · doi:10.1007/s00284-019-01679-8 · Cited by 344
Bacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Dupaul-Chicoine, J., Arabzadeh, A., Dagenais, M., Douglas, T., Champagne, C., Morizot, A., Rodrigue-Gervais, I. G., Breton, V., Colpitts, S. L., Beauchemin, N., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.013 · Cited by 342
“The commensal microbiota was required for promoting cytotoxicity after chemotherapy by modulating the tumor microenvironment (Iida et al., 2013; Viaud et al., 2013).”
BackgroundThe Oral Microbiome and Cancer
Irfan, M., Delgado, R. Z. R., & Frias-Lopez, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591088 · Cited by 341
“These gut organisms reacted by advancing the production of resistant cells, which appears to improve cyclophosphamide adequacy (176).”
BackgroundAdvancing functional and translational microbiome research using meta-omics approaches
Zhang, X., Li, L., Butcher, J., Stintzi, A., & Figeys, D. (2019) · Microbiome · doi:10.1186/s40168-019-0767-6 · Cited by 340
Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota
Xu, J., Chen, H., & Li, S. (2017) · Medicinal Research Reviews · doi:10.1002/med.21431 · Cited by 340
Individualized Medicine from Prewomb to Tomb
Topol, E. J. (2014) · Cell · doi:10.1016/j.cell.2014.02.012 · Cited by 333
The gut microbial metabolite formate exacerbates colorectal cancer progression
Ternes, D., Tsenkova, M., Pozdeev, V. I., Meyers, M., Koncina, E., Atatri, S., Schmitz, M., Karta, J., Schmoetten, M., Heinken, A., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00558-0 · Cited by 333
Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn’s Disease Patients
Liguori, G., Lamas, B., Richard, M. L., Brandi, G., da Costa, G., Hoffmann, T. W., Di Simone, M. P., Calabrese, C., Poggioli, G., Langella, P., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv209 · Cited by 332
Memory T cells: strategies for optimizing tumor immunotherapy
Liu, Q., Sun, Z., & Chen, L. (2020) · Protein & Cell · doi:10.1007/s13238-020-00707-9 · Cited by 326
Immunological Functions of the Omentum
Meza-Perez, S., & Randall, T. D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.03.002 · Cited by 326
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation
Peled, J. U., Devlin, S. M., Staffas, A., Lumish, M., Khanin, R., Littmann, E. R., Ling, L., Kosuri, S., Maloy, M., Slingerland, J. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3348 · Cited by 325
Lee, S.-H., Cho, S.-Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.-J., Jeon, B.-N., Jang, M., An, C., Lee, S., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-020-00831-6 · Cited by 325
Gut microbiome, big data and machine learning to promote precision medicine for cancer
Cammarota, G., Ianiro, G., Ahern, A., Carbone, C., Temko, A., Claesson, M. J., Gasbarrini, A., & Tortora, G. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0327-3 · Cited by 324
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Pernigoni, N., Zagato, E., Calcinotto, A., Troiani, M., Mestre, R. P., Calì, B., Attanasio, G., Troisi, J., Minini, M., Mosole, S., et al. (2021) · Science · doi:10.1126/science.abf8403 · Cited by 323
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Fecal microbiota transplantation in cancer management: Current status and perspectives
Chen, D., Wu, J., Jin, D., Wang, B., & Cao, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32003 · Cited by 321
Exploring the emerging role of the microbiome in cancer immunotherapy
Fessler, J., Matson, V., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0574-4 · Cited by 319
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Feng, M., Xiong, G., Cao, Z., Yang, G., Zheng, S., Song, X., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.006 · Cited by 318
Finding the Missing Links among Metabolites, Microbes, and the Host
Dorrestein, P. C., Mazmanian, S. K., & Knight, R. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.015 · Cited by 317
“, 2013) to the cancer drug cyclophosphamide (Viaud et al., 2013), and most likely also have an effect on immunomodulatory drugs.”
Uribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gómez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124332 · Cited by 316
“also showed that the antitumor immune response to cyclophosphamide therapy was mediated by the specific phenotype of Th17 cells (20).”
BackgroundMethodImmunogenic effects of chemotherapy-induced tumor cell death
Wang, Y.-J., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 314
Local bacteria affect the efficacy of chemotherapeutic drugs
Lehouritis, P., Cummins, J., Stanton, M., Murphy, C. T., McCarthy, F. O., Reid, G., Urbaniak, C., Byrne, W. L., & Tangney, M. (2015) · Scientific Reports · doi:10.1038/srep14554 · Cited by 313
Unexpected guests in the tumor microenvironment: microbiome in cancer
Wong-Rolle, A., Wei, H. K., Zhao, C., & Jin, C. (2021) · Protein & Cell · doi:10.1007/s13238-020-00813-8 · Cited by 313
Rutkowski, M. R., Stephen, T. L., Svoronos, N., Allegrezza, M. J., Tesone, A. J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J. M., Cadungog, M. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.009 · Cited by 311
“…mice, there is an increased systemic TLR5 signaling is driving differential tumor-promoting inflamm outcome of malignant progression. been demonstrated to have a crucial role in therapeutic responses for tumors occurring outside of the intestinal tract (Iida et al., 2013; Viaud et al., 2013).”
Tissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
Gut microbiota injury in allogeneic haematopoietic stem cell transplantation
Shono, Y., & van den Brink, M. R. M. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.10 · Cited by 309
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
Self-citationYing, M., Yu, Q., Zheng, B., Wang, H., Wang, J., Chen, S., Nie, S., & Xie, M. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.115957 · Cited by 304
Dzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K., & Trinchieri, G. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052133 · Cited by 302
Gut-Lung Axis: The Microbial Contributions and Clinical Implications
He, Y., Wen, Q., Yao, F., Xu, D., Huang, Y., & Wang, J. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2016.1176988 · Cited by 301
“In addition, gram positive bacteria can translocate through impaired intestinal mucus layer and promote the generation of immune cells such as T helper 17 (Th17) cells and memory Th1 immune responses (Atarashi et al., 2011; Viaud et al., 2013).”
BackgroundGut Microbiota in Cancer Immune Response and Immunotherapy
Zhou, C.-B., Zhou, Y.-L., & Fang, J.-Y. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.01.010 · Cited by 301
The Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Self-citationColorectal liver metastasis: molecular mechanism and interventional therapy
Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Panebianco, C., Andriulli, A., & Pazienza, V. (2018) · Microbiome · doi:10.1186/s40168-018-0483-7 · Cited by 298
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer
Qu, R., Zhang, Y., Ma, Y., Zhou, X., Sun, L., Jiang, C., Zhang, Z., & Fu, W. (2023) · Advanced Science · doi:10.1002/advs.202205563 · Cited by 297
Chalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.006 · Cited by 294
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Comparative Phylogenomics Uncovers the Impact of Symbiotic Associations on Host Genome Evolution
Delaux, P.-M., Varala, K., Edger, P. P., Coruzzi, G. M., Pires, J. C., & Ané, J.-M. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004487 · Cited by 290
Gut microbiota is critical for the induction of chemotherapy-induced pain
Shen, S., Lim, G., You, Z., Ding, W., Huang, P., Ran, C., Doheny, J., Caravan, P., Tate, S., Hu, K., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4606 · Cited by 286
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.10.018 · Cited by 283
Gajewski, T. F., Corrales, L., Williams, J., Horton, B., Sivan, A., & Spranger, S. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 278
The influence of gut microbiota on drug metabolism and toxicity
Li, H., He, J., & Jia, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 278
Dohlman, A. B., Arguijo Mendoza, D., Ding, S., Gao, M., Dressman, H., Iliev, I. D., Lipkin, S. M., & Shen, X. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.12.001 · Cited by 277
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy
Shiao, S. L., Kershaw, K. M., Limon, J. J., You, S., Yoon, J., Ko, E. Y., Guarnerio, J., Potdar, A. A., McGovern, D. P. B., Bose, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.002 · Cited by 275
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer
Bingula, R., Filaire, M., Radosevic-Robin, N., Bey, M., Berthon, J.-Y., Bernalier-Donadille, A., Vasson, M.-P., & Filaire, E. (2017) · Journal of Oncology · doi:10.1155/2017/5035371 · Cited by 270
Engineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics
Carmody, R. N., & Turnbaugh, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72335 · Cited by 268
The microbiota and microbiome in pancreatic cancer: more influential than expected
Wei, M.-Y., Shi, S., Liang, C., Meng, Q.-C., Hua, J., Zhang, Y.-Y., Liu, J., Zhang, B., Xu, J., & Yu, X.-J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1008-0 · Cited by 268
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Self-citationThe Gut Microbiota and Respiratory Diseases: New Evidence
Chunxi, L., Haiyue, L., Yanxia, L., Jianbing, P., & Jin, S. (2020) · Journal of Immunology Research · doi:10.1155/2020/2340670 · Cited by 264
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Soularue, E., Lepage, P., Colombel, J. F., Coutzac, C., Faleck, D., Marthey, L., Collins, M., Chaput, N., Robert, C., & Carbonnel, F. (2018) · Gut · doi:10.1136/gutjnl-2018-316948 · Cited by 264
Self-citationBikel, S., Valdez-Lara, A., Cornejo-Granados, F., Rico, K., Canizales-Quinteros, S., Soberón, X., Del Pozo-Yauner, L., & Ochoa-Leyva, A. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.06.001 · Cited by 263
“The gut microbial community plays an important role in protecting the host against pathogenic microbes [138,139], modulating immunity [140, 141] and regulating metabolic processes [142,143].”
BackgroundMicrobiota-Induced Type I Interferons Instruct a Poised Basal State of Dendritic Cells
Schaupp, L., Muth, S., Rogell, L., Kofoed-Branzk, M., Melchior, F., Lienenklaus, S., Ganal-Vonarburg, S. C., Klein, M., Guendel, F., Hain, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.022 · Cited by 263
Beckmann, J. S., & Lew, D. (2016) · Genome Medicine · doi:10.1186/s13073-016-0388-7 · Cited by 258
Gut microbiome and cancer immunotherapy
Li, W., Deng, Y., Chu, Q., & Zhang, P. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.015 · Cited by 253
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Self-citationNanotechnology intervention of the microbiome for cancer therapy
Song, W., Anselmo, A. C., & Huang, L. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0589-5 · Cited by 246
Weber, D., Jenq, R. R., Peled, J. U., Taur, Y., Hiergeist, A., Koestler, J., Dettmer, K., Weber, M., Wolff, D., Hahn, J., et al. (2017) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.02.006 · Cited by 245
Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics
García-González, A. P., Ritter, A. D., Shrestha, S., Andersen, E. C., Yilmaz, L. S., & Walhout, A. J. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.046 · Cited by 243
Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer
Koliarakis, I., Messaritakis, I., Nikolouzakis, T. K., Hamilos, G., Souglakos, J., & Tsiaoussis, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174146 · Cited by 242
Microbiota-mediated inflammation and antimicrobial defense in the intestine
Caballero, S., & Pamer, E. G. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120238 · Cited by 238
The Gut Microbiota: Emerging Evidence in Autoimmune Diseases
Zhang, X., Chen, B.-D., Zhao, L.-D., & Li, H. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.04.001 · Cited by 232
Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation
Shalapour, S., & Karin, M. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.021 · Cited by 228
Zhong, W., Wu, K., Long, Z., Zhou, X., Zhong, C., Wang, S., Lai, H., Guo, Y., Lv, D., Lu, J., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01289-w · Cited by 223
The gut microbiota and gastrointestinal surgery
Guyton, K., & Alverdy, J. C. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.139 · Cited by 221
Microbiome—Microbial Metabolome—Cancer Cell Interactions in Breast Cancer—Familiar, but Unexplored
Mikó, E., Kovács, T., Sebő, É., Tóth, J., Csonka, T., Ujlaki, G., Sipos, A., Szabó, J., Méhes, G., & Bai, P. (2019) · Cells · doi:10.3390/cells8040293 · Cited by 220
Commensal microbes provide first line defense against Listeria monocytogenes infection
Becattini, S., Littmann, E. R., Carter, R. A., Kim, S. G., Morjaria, S. M., Ling, L., Gyaltshen, Y., Fontana, E., Taur, Y., Leiner, I. M., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20170495 · Cited by 219
The promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Integrative methods for analyzing big data in precision medicine
Gligorijević, V., Malod‐Dognin, N., & Pržulj, N. (2016) · PROTEOMICS · doi:10.1002/pmic.201500396 · Cited by 216
Elinav, E., Garrett, W. S., Trinchieri, G., & Wargo, J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0155-3 · Cited by 215
Role of lung and gut microbiota on lung cancer pathogenesis
Zhao, Y., Liu, Y., Li, S., Peng, Z., Liu, X., Chen, J., & Zheng, X. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03644-0 · Cited by 212
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer
Goc, J., Lv, M., Bessman, N. J., Flamar, A.-L., Sahota, S., Suzuki, H., Teng, F., Putzel, G. G., Eberl, G., Withers, D. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.029 · Cited by 212
Self-citationThe intestinal microbiota: its role in health and disease
Biedermann, L., & Rogler, G. (2015) · European Journal of Pediatrics · doi:10.1007/s00431-014-2476-2 · Cited by 211
Introduction to host microbiome symbiosis in health and disease
Malard, F., Dore, J., Gaugler, B., & Mohty, M. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00365-4 · Cited by 209
Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208
“a causality between ATB and primary resistance to ICI and immunogenic chemotherapy.(8,12,24,25) Lastly, in our study, the frequency of immune-related adverse effects was too small and we were unable to evaluate the association between ATB and adverse events.”
BackgroundMicrobiota effects on cancer: From risks to therapies
Rea, D., Coppola, G., Palma, G., Barbieri, A., Luciano, A., Del Prete, P., Rossetti, S., Berretta, M., Facchini, G., Perdonà, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24681 · Cited by 208
“A study based on GF mice and specific pathogen free mice (SPF) evidenced CTK therapeutic efficacy has been improved by some gram-positive bacteria: after CTK induces a disrupt of intestinal epithelial barrier, bacteria and their metabolites translocate through it and stimulate systemically Th17 and Th1 cells to a stra…”
BackgroundYuan, L., Zhang, S., Li, H., Yang, F., Mushtaq, N., Ullah, S., Shi, Y., An, C., & Xu, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.165 · Cited by 208
The microbiome in prostate inflammation and prostate cancer
Porter, C. M., Shrestha, E., Peiffer, L. B., & Sfanos, K. S. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0041-1 · Cited by 207
The role of the vaginal microbiome in gynaecological cancer
Champer, M., Wong, A., Champer, J., Brito, I., Messer, P., Hou, J., & Wright, J. (2018) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14631 · Cited by 206
Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment
Laborda-Illanes, A., Sanchez-Alcoholado, L., Dominguez-Recio, M. E., Jimenez-Rodriguez, B., Lavado, R., Comino-Méndez, I., Alba, E., & Queipo-Ortuño, M. I. (2020) · Cancers · doi:10.3390/cancers12092465 · Cited by 206
Evaluation of the association of chronic inflammation and cancer: Insights and implications
Nigam, M., Mishra, A. P., Deb, V. K., Dimri, D. B., Tiwari, V., Bungau, S. G., Bungau, A. F., & Radu, A.-F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115015 · Cited by 205
Yamamura, K., Izumi, D., Kandimalla, R., Sonohara, F., Baba, Y., Yoshida, N., Kodera, Y., Baba, H., & Goel, A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0318 · Cited by 202
Haiser, H. J., Seim, K. L., Balskus, E. P., & Turnbaugh, P. J. (2014) · Gut Microbes · doi:10.4161/gmic.27915 · Cited by 197
Metadata
- Authors
- Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P.-L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., Bizet, C., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Opolon, P., Yessaad, N., Vivier, E., Ryffel, B., Elson, C. O., Doré, J., Kroemer, G., Lepage, P., Boneca, I. G., Ghiringhelli, F., & Zitvogel, L.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Agency for Science, Technology and Research (SG)
- Institut National de la Santé et de la Recherche Médicale, U866, Centre Georges François Leclerc, Dijon, France.
- Service de Microbiologie, Institut Gustave Roussy, Villejuif, France.
- Institut Gustave Roussy (FR)
- Institut Pasteur (FR)
- Nimalerie Centrale, Institut Pasteur, Paris, France.
- Institut National de la Recherche Agronomique, Micalis–UMR1319, 78350 Jouy-en-Josas, France.
- Centre National de la Recherche Scientifique (FR)
- Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université UM2, Marseille, France.
- Université d'Orléans (FR)
- University of Alabama at Birmingham (US)
- AgroParisTech (FR)
- Corresponding author
- Ghiringhelli, François
- Zitvogel, Laurence
- ORCID
- Mignot, Grégoire
- Yamazaki, Takahiro
- Daillère, Romain
- Hannani, Dalil
- Pfirschke, Christina
- Engblom, Camilla
- Schlitzer, Andreas
- Ginhoux, Florent
- Woerther, Paul-Louis
- Eberl, Gérard
- Clermont, Dominique
- Opolon, Paule
- Ryffel, Bernhard
- Elson, Charles O.
- Kroemer, Guido
- Lepage, Patricia
- Boneca, Ivo Gomperts
- Ghiringhelli, François
- Zitvogel, Laurence
- Venue
- Science
- Published
- 2013-11-22
- Volume
- 342
- Issue
- 6161
- Pages
- 971-976
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4048947
- OpenAlex
- W2059128083
- Cited by
- 2,050
- References
- 43
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 176 · 2023: 216 · 2022: 234 · 2021: 217 · 2020: 220 · 2019: 183 · 2018: 137 · 2017: 116 · 2016: 98 · 2015: 101 · 2014: 69 · 2013: 6
- FWCI
- 40.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (acceptedVersion, other-oa)
- HAL AMU (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-11-PHUC-0002)
- National Cancer Institute (P50CA086355)
- National Institute of Allergy and Infectious Diseases (R01AI084880)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK071176)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cyclophosphamide, gut microbiota, antitumor immunity, Gram-positive bacteria, Th17 cells, memory T cells, secondary lymphoid organs, bacterial translocation, germ-free mice, antibiotic therapy, adoptive transfer, small intestine
- MeSH terms
- Animals, Anti-Bacterial Agents, Antineoplastic Agents, Cyclophosphamide, Germ-Free Life, Gram-Positive Bacteria, Immunologic Memory, Immunosuppressive Agents, Intestine, Small, Lymphoid Tissue, Neoplasms, Bacterial Translocation, Adoptive Transfer, Mice, Th17 Cells, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.